The safety of rituximab in hepatitis C virus (HCV) positive patients

Journal of Applied Research

Volumn 4, Issue 3, 2004, Pages 470-475

  Pérez Calvo, Juan ^a   Murashige, Naoko ^b   Fuertes, Miguel Angel ^a   Kikuchi, Daisuke ^c   Benito, Rafael ^a   Kusumi, Eiji ^c   Kami, Masahiro ^b   Taniguchi, Shuichi ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c TORANOMON HOSPITAL   (Japan)

Author keywords

Anti CD20 treatment; Chronic HCV infection, hepatitis C; Rituximab

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; PIRARUBICIN; PREDNISOLONE; PREDNISONE; RIBAVIRIN; RITUXIMAB; VINCRISTINE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHILL; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL EXAMINATION; CRYOGLOBULINEMIA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HEPATITIS; HEPATITIS C; HUMAN; LYMPHOMA; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; OPPORTUNISTIC INFECTION; SYNCOPE; VIRUS LOAD;

EID: 4644286318     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
2. Pawlotsky JM, Roudot-Thoraval F, Simmonds P, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med. 1995;122:169-173.
3. Michalska Z, Stalke P, Witczak-Malinowska K, et al. Autoimmune reactions in HBV and HCV. Med Sci Monit. 2001;7(suppl 1):175-180.
4. Chen M, Sallberg M, Sonnerborg A, et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology. 1999;116:135-143.
5. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type 11 mixed cryoglobulinemia. Blood. 2003;101:3827-3834.
6. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood. 2003;101:3818-3826.
7. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood. 2000;96:1184-1186.
8. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med. 2001;345:1000.
9. Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica. 2000;85:894-895.
10. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001;344:68-69.
11. Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol. 2001;80:549-552.
12. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
13. Perez-Calvo J, Lasierra P, Moros M, Inigo P. Role of ribavirin in membranoproliferative glomerulonephritis associated with hepatitis C virus infection refractory to α-interferon. Nephron. 2002;92:459-462.
14. Kami M, Hamaki T, Murashige N, et al. Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection. Hematol J. 2003;4:159-162.
15. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis. 2003;7:261-287.
16. Thiel J, Peters T, Mas Marques A, Rosler B, Peter HH, Weiner SM. Kinetics of hepatitis C (HCV) viraemia and quasispecies during treatment of HCV associated cryoglobulinaemia with pulse cyclophosphamide. Ann Rheum Dis. 2002;61:838-8341.
17. Rosenstock JL, Stern L, Sherman WH, Appel GB, Radhakrishnan J. Fludarabine treatment of cryoglobulinemic glomerulonephritis. Am J Kidney Dis. 2002;40:644-648.
18. De Francesco R, Rice CM. New therapies on the horizon for hepatitis C: are we close? Clin Liver Dis. 2003;7:211-242, xi.
19. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100:2257-2259.